

## **Ensemble Discovery Appoints Nick Terrett, PhD as Chief Scientific Officer**

**Cambridge, MA (May 22, 2006)** —Ensemble Discovery Corporation today announced the appointment of Nick Terrett, PhD to the newly created role of Chief Scientific Officer. In this capacity, Dr. Terrett will oversee all of Ensemble Discovery's pharmaceutical research and development activities.

“We are extremely fortunate to add Nick Terrett's talent and experience to our senior management team,” said Richard F. Begley, PhD, President and CEO. “Nick's extensive experience in drug discovery and technology is a perfect fit for Ensemble as we develop applications utilizing our proprietary DNA Programmed Chemistry platform in drug discovery.”

Dr. Terrett comes to Ensemble from Pfizer Inc. where he has spent more than 20 years in various research capacities, including, most recently, as the head of the Chemical Sciences Department in the Pfizer Research Technology Center (RTC). Prior roles at Pfizer include, among others, being the chemistry team leader for the project that discovered sildenafil (Viagra<sup>TM</sup>), being Section Head of Pfizer's first combinatorial chemistry group, and managing several other research groups within Pfizer.

Dr. Terrett received his PhD in Organic Chemistry from Corpus Christi College, University of Cambridge, UK, and a BA in Natural Sciences from Pembroke College, University of Cambridge, UK. He has authored and co-authored numerous scientific papers as well as written a textbook on Combinatorial Chemistry.

### **About Ensemble Discovery**

Ensemble Discovery Corporation, located in Cambridge, MA, is developing a novel approach to chemical discovery based on a highly integrated set of processes that combine chemistry, biology and nanotechnology. Central to its approach is DNA Programmed Chemistry (DPC), an innovative method for chemical synthesis based on the groundbreaking work of Professor David Liu of Harvard University. Ensemble aims to generate new products that address significant unmet needs in therapeutics, detection and other specialty chemical markets.

### **For More Information, Contact:**

Richard F. Begley, Ph.D.  
Ensemble Discovery Corporation  
(617) 492-6977  
[rbegley@enssemblediscovery.com](mailto:rbegley@enssemblediscovery.com)